Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate, selonabant, is a small-molecule antagonist of the cannabinoid type-1 (CB1) receptor and is in a Phase II clinical trial. The company was incorporated in 2020 and is headquartered in Lakeway, Texas.